Sunmax Biotechnology Co Ltd (4728) - Total Liabilities
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has total liabilities worth NT$454.35 Million TWD (≈ $14.31 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 4728 net asset momentum to track the company's year-over-year net asset growth rate.
Sunmax Biotechnology Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 4728 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Sunmax Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
China | CN¥1.40 Billion |
|
Tianjin Lisheng Pharmaceutical Co Ltd
SHE:002393
|
China | CN¥893.57 Million |
|
MNTN, Inc.
NYSE:MNTN
|
USA | $56.49 Million |
|
Zhejiang Kaier New Materials
SHE:300234
|
China | CN¥191.97 Million |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
Brightspire Capital Inc
NYSE:BRSP
|
USA | $2.74 Billion |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
USA | $662.82 Million |
|
Bank of Kaohsiung Ltd
TW:2836
|
Taiwan | NT$329.13 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Sunmax Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4728 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunmax Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual total liabilities of Sunmax Biotechnology Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$337.82 Million ≈ $10.64 Million |
-53.91% |
| 2023-12-31 | NT$732.99 Million ≈ $23.09 Million |
+56.62% |
| 2022-12-31 | NT$468.00 Million ≈ $14.74 Million |
+1.64% |
| 2021-12-31 | NT$460.44 Million ≈ $14.51 Million |
-3.12% |
| 2020-12-31 | NT$475.27 Million ≈ $14.97 Million |
+9.05% |
| 2019-12-31 | NT$435.82 Million ≈ $13.73 Million |
+296.62% |
| 2018-12-31 | NT$109.88 Million ≈ $3.46 Million |
+24.56% |
| 2017-12-31 | NT$88.22 Million ≈ $2.78 Million |
+109.06% |
| 2016-12-31 | NT$42.20 Million ≈ $1.33 Million |
-4.81% |
| 2015-12-31 | NT$44.33 Million ≈ $1.40 Million |
-- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.